Equities analysts expect Fennec Pharmaceuticals Inc (NASDAQ:FENC) to report earnings per share of ($0.15) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Fennec Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.16) and the highest estimate coming in at ($0.13). Fennec Pharmaceuticals posted earnings per share of ($0.09) during the same quarter last year, which would indicate a negative year over year growth rate of 66.7%. The firm is scheduled to issue its next quarterly earnings results on Monday, May 13th.
According to Zacks, analysts expect that Fennec Pharmaceuticals will report full-year earnings of ($0.66) per share for the current year, with EPS estimates ranging from ($0.76) to ($0.56). For the next fiscal year, analysts anticipate that the firm will post earnings of $1.65 per share, with EPS estimates ranging from $0.08 to $3.21. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Fennec Pharmaceuticals.
Fennec Pharmaceuticals (NASDAQ:FENC) last issued its quarterly earnings data on Wednesday, March 13th. The company reported ($0.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.01).
Shares of NASDAQ:FENC traded down $0.02 during trading hours on Friday, hitting $4.85. The company’s stock had a trading volume of 33,844 shares, compared to its average volume of 58,778. Fennec Pharmaceuticals has a 52 week low of $4.61 and a 52 week high of $14.99. The firm has a market cap of $96.52 million, a P/E ratio of -9.70 and a beta of -0.23.
Several institutional investors have recently modified their holdings of FENC. Northern Trust Corp acquired a new position in shares of Fennec Pharmaceuticals in the 2nd quarter valued at $1,058,000. venBio Select Advisor LLC raised its stake in shares of Fennec Pharmaceuticals by 8.1% during the 4th quarter. venBio Select Advisor LLC now owns 1,105,999 shares of the company’s stock worth $7,056,000 after buying an additional 83,333 shares during the last quarter. United Services Automobile Association raised its stake in shares of Fennec Pharmaceuticals by 87.4% during the 4th quarter. United Services Automobile Association now owns 154,190 shares of the company’s stock worth $984,000 after buying an additional 71,922 shares during the last quarter. Opaleye Management Inc. raised its stake in shares of Fennec Pharmaceuticals by 3.2% during the 3rd quarter. Opaleye Management Inc. now owns 975,000 shares of the company’s stock worth $7,995,000 after buying an additional 30,000 shares during the last quarter. Finally, Weiss Multi Strategy Advisers LLC acquired a new position in shares of Fennec Pharmaceuticals during the 4th quarter worth $160,000. 48.99% of the stock is currently owned by hedge funds and other institutional investors.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Further Reading: Why is the Consumer Price Index (CPI) important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.